Continuous glucose monitors cost so much because you’re paying for precision biochemistry, strict regulatory approval, and a device designed to be thrown away every 10 to 14 days. Depending on your insurance, a month of CGM use runs anywhere from $0 to over $300 out of pocket, and the sticker price without coverage is significantly higher. Several factors stack on top of each other to create that price tag.
What’s Actually Inside a CGM Sensor
A CGM sensor is not a simple piece of plastic. The core of most systems is a platinum-iridium wire just 0.125 mm in diameter, coated with layers of specialized materials that each serve a specific function. The wire acts as an electrode, with the enzyme glucose oxidase immobilized on its surface to react with glucose in the fluid beneath your skin. A silver and silver chloride wire wraps around this active electrode to complete the electrical circuit. On top of all that, protective polymer coatings prevent your body’s proteins from fouling the sensor and block interference from substances like uric acid and acetaminophen.
Every one of these layers has to be manufactured at microscopic scale with extreme consistency. If the enzyme coating is slightly too thick or thin, glucose readings drift. If the protective layer fails, the sensor gives false readings from other chemicals in your body. This isn’t like assembling a fitness tracker from off-the-shelf chips. It’s closer to building a tiny, disposable chemistry lab that has to work reliably inside living tissue for up to two weeks.
Regulatory Approval Costs Millions
CGMs that replace fingerstick testing are classified as high-risk medical devices, the same regulatory category as pacemakers and cochlear implants. Getting a new CGM through FDA approval takes one to three years of clinical trials alone. Before those trials even begin, a completely novel device typically spends two to three years in preclinical development and animal testing, at a cost of $10 to $20 million just for that early stage.
Those development costs don’t disappear once a device hits the market. Manufacturers spread them across the price of every sensor sold, often for years. And the process repeats with each new generation. When Dexcom moves from the G6 to the G7, or Abbott updates the Libre platform, much of that regulatory and testing work starts over. Consumers ultimately absorb those costs through higher per-sensor pricing.
The Replacement Cycle Adds Up Fast
Unlike a blood glucose meter that lasts for years, CGM sensors are disposable by design. A Dexcom G7 sensor lasts 10 days. A FreeStyle Libre 3 sensor lasts 14 days. That means you need roughly 26 to 37 sensors per year just to maintain continuous coverage. Some older systems also require a separate transmitter that costs more upfront, though it lasts about 90 days before replacement.
Research from a cost-effectiveness analysis published in Diabetes Care estimated that annual CGM costs could reach around $3,271 even when users stretched sensor life beyond the recommended window. That figure assumed extending sensors from the standard 7 days (on older models) to 10 days. With current 10- and 14-day sensors, the annual math still lands in a similar range for uninsured users. This recurring replacement model is fundamentally different from buying a single device, and it’s one of the biggest reasons CGMs feel so expensive over time.
Limited Competition Keeps Prices High
The CGM market has been dominated by two companies for years: Dexcom and Abbott. When only two manufacturers make a product that millions of people need, there’s little pressure to slash prices. Both companies have extensive patent portfolios covering their sensor chemistry, algorithms, and hardware designs, which makes it difficult for competitors to enter the market quickly.
The regulatory burden reinforces this. A startup can’t simply build a better sensor and start selling it. The years-long, multimillion-dollar approval process acts as a barrier to entry, keeping the number of competitors small and giving existing players more control over pricing.
Insurance Coverage Varies Widely
What you actually pay depends enormously on your insurance situation, which is part of why CGM pricing feels opaque and frustrating. Most commercially insured patients using the FreeStyle Libre 3 pay between $0 and $75 per month. Dexcom offers programs bringing the G7 down to $89 per month for insured users, with pharmacy savings programs for those without CGM coverage.
Medicare covers CGMs if you take insulin or have a history of low blood sugar episodes, and your provider confirms you’ve been trained to use the device. But if you don’t meet those criteria, or if you’re uninsured, you’re facing the full retail price. The gap between what an insured patient pays and what an uninsured patient pays can be hundreds of dollars per month, making the same device affordable for one person and prohibitive for another.
Over-the-Counter Options Are Changing the Math
A newer category of CGMs designed for people who don’t use insulin is starting to shift pricing. Abbott’s FreeStyle Lingo, available without a prescription, sells for about $49 for a single 14-day sensor or $89 for a month’s supply of two sensors. Dexcom’s Stelo is another over-the-counter option targeting the wellness and pre-diabetes market.
These devices are generally simpler than prescription CGMs. They may lack features like real-time alarms for dangerous glucose levels, which reduces their regulatory classification and manufacturing complexity. But they represent the first real movement toward lower price points in a market that has been stubbornly expensive. For people with Type 1 or Type 2 diabetes who depend on CGM data to dose insulin, though, these stripped-down models aren’t a substitute for prescription systems, and the higher costs of those systems remain.
Why the Price Isn’t Just About the Sensor
It’s tempting to look at a tiny sensor patch and wonder how it could possibly cost what it does. But the price reflects layers beyond raw materials. Algorithms that convert electrical signals into accurate glucose numbers require continuous software development. Bluetooth connectivity, smartphone app maintenance, and cloud data storage all have ongoing costs. Customer support for a medical device carries higher standards and liability than consumer electronics.
There’s also the cost structure that comes with being a medical device sold through pharmacies and durable medical equipment suppliers. Each intermediary in that chain takes a margin. A sensor that costs a manufacturer a fraction of its retail price still passes through distributors, pharmacy benefit managers, and retailers before reaching you, with each step adding cost. This distribution model, inherited from the broader medical device industry, inflates what you see at the counter compared to what the sensor costs to produce.